Opinion: New drug development: ‘It’s the ecosystem, stupid’
Drug development occurs in a vibrant but fragile environment made up of many inhabitants. You can't fundamentally alter one without affecting all of the others.
A trio of biopharma observers recently published in STAT an analysis relevant to the ongoing drug pricing debate in Washington. The response has not been pretty. In short, the authors suggest that since two reviewed pharmaceutical companies provided relatively little innovation in drug development and were not responsible for the original invention of some of their products, current proposals to lambaste the industry are warranted — with no side effects on innovation.
This follows from researchers at West Health Policy Center and Johns Hopkins Bloomberg School of Public Health which suggested that removing $1 trillion from the by a leading venture capitalist.
